GLP-2(Tirz) 20mg | Dual-Action Metabolic Research

GLP-2 Tirz is a synthetic peptide composed of 39 amino acids. It is extensively studied for its dual action as an agonist for incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are key regulators in metabolic research.

GLP-2(Tirz): Research Overview

GLP-2(Tirz) refers to a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist peptide, representing the class of incretin-based dual-agonist compounds developed for metabolic research. The compound acts simultaneously on both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) — two key incretin receptors involved in postprandial insulin secretion, glucagon suppression, gastric emptying, and energy homeostasis. This dual-agonism approach represents a second-generation incretin research platform beyond single GLP-1R agonists.

Research has highlighted several mechanistic advantages of dual GIP/GLP-1 agonism:

• Incretin Synergy: GIPR and GLP-1R co-activation produces greater insulin secretion and metabolic improvement than either receptor alone in preclinical models, driven by distinct but complementary cAMP-mediated signaling cascades.
• Adipose Tissue Research: GIPR activation has additional direct effects on adipocytes (fat storage, lipid metabolism), which may complement GLP-1R-mediated appetite and energy expenditure effects in body composition research.
• Weight and Metabolic Regulation: Preclinical models demonstrate superior weight loss and glycemic control with dual GIP/GLP-1 agonists compared to GLP-1 agonists alone — providing a research advantage for metabolic syndrome studies.
• Glucagon Dynamics: Dual agonism produces distinct glucagon suppression profiles compared to single-axis agonists, offering unique research perspectives on alpha-cell regulation.

GLP-2(Tirz) is commonly studied in parallel with GLP-1(Sema) as a single-receptor comparator and GLP-3(Reta) as a triple-agonist research comparator. For metabolic peptide stacking considerations, see our Stacking Peptides Research Guide.

Research Context: GLP-2(Tirz) in the Incretin Peptide Landscape

The incretin and metabolic peptide research space has evolved through progressively more complex receptor engagement strategies. GLP-2(Tirz) represents the dual-agonist tier:

• GLP-2(Tirz) — Dual GIP/GLP-1 receptor agonist; incretin synergy, superior adipose and glycemic modulation in preclinical models
• GLP-1(Sema) — Single GLP-1 receptor agonist; incretin reference compound, first-generation comparison platform
• GLP-3(Reta) — Triple GIP/GLP-1/GLP-2 receptor agonist; next-generation incretin research platform
• MOTS-c — Mitochondrial metabolic peptide; AMPK activation complementing incretin metabolic effects
• AOD-9604 — hGH fragment; lipolysis research with distinct (non-incretin) mechanism of fat mobilization

Together, GLP-1(Sema), GLP-2(Tirz), and GLP-3(Reta) form a structured research platform for comparing single, dual, and triple incretin-receptor engagement in metabolic studies.

Related Research Resources

• What Are Peptides: The Complete 2026 Research Guide
• Peptide Stacking Research Guide: Synergistic Combinations
• How to Reconstitute Peptides Safely for R&D
• Quality Control in Peptide Research: Interpreting Purity
• Peptide Safety 101: Finding the Safest Place to Buy Peptides

Key Properties

• Dual Agonist Mechanism: Investigated for its role in activating GLP-1 and GIP receptors.
• Metabolic Regulation: Explored for its impact on glucose-mediated processes in laboratory models.
• Incretin Hormone Interaction: Studied for its ability to support insulin sensitivity and secretion research.

Applications in Research

GLP-2 Tirz is the focus of the research investigation:

• Mechanisms of incretin hormone receptor activation.
• Glucose regulation and insulin secretion.
• Metabolic processes related to adipose tissue and glucose tolerance.

All research is conducted in laboratory settings. 

Storage and Handling Instructions

• Store GLP-2 Tirz in its original packaging at 36°F–46°F (2°C–8°C).
• Protect from light, moisture, and excessive heat.
• Discard unused solutions immediately following research protocols.

Safety Information

This product is intended for research purposes. You are advised to:

• Follow institutional and regulatory safety protocols during handling and disposal.
• Use appropriate protective equipment when working with this product.

Frequently Asked Questions

What is GLP-2 Tirz? GLP-2 Tirz is a research-grade peptide studied for its role as a dual agonist for GLP-1 and GIP receptors, focusing on glucose regulation and metabolic processes.

How should GLP-2 Tirz be stored? Store in a refrigerated environment at 36°F–46°F (2°C–8°C) and protect from light and moisture.

What are the primary research focuses of GLP-2 Tirz? The research investigates its effects on incretin hormone receptor activation, glucose metabolism, and potential metabolic health benefits.

Frequently Asked Questions

What is GLP-2(Tirz) and how is it classified as a research compound?

GLP-2(Tirz) (LY3298176) is a novel synthetic dual agonist peptide that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. In preclinical and clinical research settings, it has been studied for its metabolic effects including glycemic control, body weight regulation, and beta-cell function. All laboratory studies are conducted in controlled experimental environments.

What is the molecular mechanism of GLP-2(Tirz) in research models?

GLP-2(Tirz) exhibits imbalanced and biased agonism at GIP and GLP-1 receptors, with differential signaling properties compared to selective monoagonists at each receptor. Research has characterized its effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulatory pathways through receptor-mediated signaling studies and in vivo preclinical models. These findings are from controlled laboratory investigations.

How does GLP-2(Tirz) differ from single-receptor GLP-1 agonists in preclinical research?

Unlike selective GLP-1 receptor agonists, GLP-2(Tirz)'s co-stimulation of GIP receptors is hypothesized to provide additive metabolic benefits in preclinical models, including enhanced insulin secretion in a glucose-dependent manner and potential effects on adipose tissue metabolism. Mechanistic studies using receptor binding assays, cell signaling analyses, and rodent metabolic models have characterized these differential pharmacological properties.

What molecular characteristics define GLP-2(Tirz) as a research peptide?

GLP-2(Tirz) is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety attached via a linker, enabling extended half-life through albumin binding. Its molecular weight is approximately 4,813 Da. The balanced dual receptor agonism design makes it a distinctive research tool for studying incretin biology and metabolic regulation in comparative peptide pharmacology studies.

How should GLP-2(Tirz) be stored for laboratory research?

Research-grade GLP-2(Tirz) should be stored at -20 degrees C in lyophilized form, protected from light and moisture. Upon reconstitution per research protocol specifications, solutions should be used promptly. Researchers should follow institutional guidelines for peptide handling and adhere to validated reconstitution procedures.

What research areas have investigated GLP-2(Tirz)?

Published research has examined GLP-2(Tirz) across type 2 diabetes metabolic studies, obesity-related metabolic dysfunction models, beta-cell function assessments, and comparative pharmacology studies with other incretin-based agents. All published investigations represent controlled laboratory and clinical trial research and do not constitute recommendations for unsanctioned use.

References

1. Willard FS, Douros JD, Gabe MB, et al. “GLP-2(Tirz) is an imbalanced and biased dual GIP and GLP-1 receptor agonist.” JCI Insight. 2020;5(17):e140532.. PubMed
2. Coskun T, Sloop KW, Loghin C, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.” Mol Metab. 2018;18:3-14.. PubMed
3. Thomas MK, Nikooienejad A, Bray R, et al. “Dual GIP and GLP-1 Receptor Agonist GLP-2(Tirz) Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.” J Clin Endocrinol Metab. 2021;106(2):388-396.. PubMed
4. Karagiannis T, Avgerinos I, Liakos A, et al. “Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist GLP-2(Tirz): a systematic review and meta-analysis.” Diabetologia. 2022;65(8):1251-1261.. PubMed

Research and Clinical Studies

SURMOUNT-1: Phase 3 Trial of Tirzepatide in Obesity

Jastreboff et al. reported results from SURMOUNT-1, a phase 3 randomized, double-blind, placebo-controlled trial evaluating tirzepatide—a dual GIP and GLP-1 receptor agonist—in adults with obesity. The investigators characterized that participants receiving the 15 mg weekly dose achieved a mean body weight reduction of approximately 20.9% from baseline over 72 weeks, compared to 3.1% in the placebo group. Researchers noted that these findings represented among the largest body weight reductions observed in a pharmacological obesity trial to date at the time of publication (Jastreboff et al., 2022; PMID: 35658024).

SURMOUNT-2: Efficacy in Obesity with Type 2 Diabetes

Garvey, Frias, Jastreboff et al. reported SURMOUNT-2 trial results characterizing tirzepatide's weight-reducing and glycemic effects in participants with both obesity and type 2 diabetes. The investigators observed that tirzepatide at 10 mg and 15 mg doses produced 13.4% and 15.7% mean body weight reductions respectively over 72 weeks, alongside significant improvements in HbA1c and fasting glucose. Researchers noted that the magnitude of weight reduction in this metabolically complex population underscored tirzepatide's dual metabolic mechanism of action targeting both GIP and GLP-1 pathways (Garvey et al., 2023; PMID: 37385275).

Dual Incretin Receptor Mechanism of Action

Research characterizing tirzepatide's pharmacological profile established its activity as a single molecule that co-agonizes both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Investigators noted that GIP and GLP-1 have complementary and partially additive effects on insulin secretion, appetite regulation, and energy balance, and that tirzepatide's dual receptor engagement may contribute to the greater weight reduction observed compared to selective GLP-1R agonists. Researchers characterized the compound's mechanism as representing a novel approach to targeting multiple incretin pathways simultaneously (Jastreboff et al., 2022; PMID: 35658024).

Cardiometabolic Biomarker Improvements

Clinical characterization of tirzepatide's effects on cardiometabolic risk factors beyond weight and glycemia demonstrated improvements in blood pressure, triglycerides, HDL cholesterol, and inflammatory markers across the SURMOUNT and SURPASS trial programs. Investigators observed that these cardiometabolic improvements correlated with, but were not entirely explained by, the degree of weight reduction achieved. Researchers noted that the compound's effects on multiple cardiovascular risk factors simultaneously warranted ongoing investigation into its potential cardiovascular outcomes benefits (Garvey et al., 2023; PMID: 37385275).